BRAF and pneumocystosis: Papillary craniopharyngioma (PCP), defined by near-universal <i>BRAF V600E</i> mutations, exhibits profound and rapid responses to combined BRAF and MEK inhibition, with objective response rates exceeding 90% in prospective studies.